After a non-Hodgkin’s lymphoma diagnosis, the hematologist-oncologist will review available information from a biopsy, images, and other tests to determine the stage of the cancer. This will be used to plan the best treatment path. Staging considers several factors that identify the overall extent of the cancer.
Staging non-Hodgkin’s lymphoma (NHL) may involve one or more of the following tests:
Staging is a way of describing how far the cancer spread (metastasized). The stage is based on where lymphoma cells are found in the lymph nodes or in other organs or tissues. It also depends on how many areas are affected. Doctors use the stage and other factors to determine what treatments will likely be the most effective for your cancer.
The Lugano classification, based on the older Ann Arbor system, is currently used for staging lymphoma. The stages of non-Hodgkin’s lymphoma describe the extent of the spread of the tumor using the Roman numerals I, II, III, or IV (1 through 4). Unlike other cancers, a stage IV lymphoma diagnosis does not reflect how well or poorly the patient will respond to treatment but rather the specific location of the disease. Even though stage IV lymphomas are the most advanced, they can still be treated successfully.
Either of these conditions applies:
Either of these conditions applies:
The lymphoma is in lymph node areas on both sides of the diaphragm (stage III), or lymphoma cells have spread to several parts of one or more organs or tissues (in addition to the lymph nodes). It may be found in the liver, blood, or bone marrow. (stage IV). Stage III-IV lymphomas are common, still very treatable, and often curable, depending on the NHL subtype. Because stage III and stage IV have the same treatment and prognosis, they are now considered a single category.
Cancer that grows larger or spreads while the patient is being treated for the original lymphoma is referred to as progressive disease or refractory NHL.
This describes cancer that comes back after treatment. It may return to the area where it first started or somewhere else in the body. Sometimes, recurrent lymphoma may need to be re-staged using the system above.
In addition to where the cancer is physically located throughout the patient’s body, the oncology team will also use some indicators as to the likely outcome of their treatments.
An assessment is performed to see how well the patient can carry out daily activities. This is evaluated on a functional assessment scale. A common scale that is used is the Eastern Cooperative Oncology Group (ECOG) Performance Status.
The (ECOG) Performance Status grades are as follows:
A lower score indicates a better functional status. Typically, the better someone is able to walk and care for themselves, the better the prognosis.
Your hematologist-oncologist will recommend a set of treatments that are most likely to be effective based on your stage and overall prognosis. Learn more about lymphoma treatments.
Related Reading: